DK2812431T3 - Peptidblandinger til generering af multivirale ctl'er med bred specificitet - Google Patents

Peptidblandinger til generering af multivirale ctl'er med bred specificitet Download PDF

Info

Publication number
DK2812431T3
DK2812431T3 DK13746524.1T DK13746524T DK2812431T3 DK 2812431 T3 DK2812431 T3 DK 2812431T3 DK 13746524 T DK13746524 T DK 13746524T DK 2812431 T3 DK2812431 T3 DK 2812431T3
Authority
DK
Denmark
Prior art keywords
multiviral
peptid
ctls
mixtures
generation
Prior art date
Application number
DK13746524.1T
Other languages
English (en)
Inventor
Anne Marie Leen
Juan Fernando Vera Valdes
Cliona M Rooney
Ulrike Gerdemann
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Application granted granted Critical
Publication of DK2812431T3 publication Critical patent/DK2812431T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/135—Respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK13746524.1T 2012-02-09 2013-02-08 Peptidblandinger til generering af multivirale ctl'er med bred specificitet DK2812431T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261596875P 2012-02-09 2012-02-09
PCT/US2013/025342 WO2013119947A1 (en) 2012-02-09 2013-02-08 Pepmixes to generate multiviral ctls with broad specificity

Publications (1)

Publication Number Publication Date
DK2812431T3 true DK2812431T3 (da) 2019-10-14

Family

ID=48948057

Family Applications (2)

Application Number Title Priority Date Filing Date
DK13746524.1T DK2812431T3 (da) 2012-02-09 2013-02-08 Peptidblandinger til generering af multivirale ctl'er med bred specificitet
DK19178235.8T DK3591047T3 (da) 2012-02-09 2013-02-08 Peptidblandinger til generering af multivirale CTL¿er med bred specificitet

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK19178235.8T DK3591047T3 (da) 2012-02-09 2013-02-08 Peptidblandinger til generering af multivirale CTL¿er med bred specificitet

Country Status (9)

Country Link
US (4) US20150010519A1 (da)
EP (3) EP3591047B1 (da)
DK (2) DK2812431T3 (da)
ES (2) ES2928851T3 (da)
HR (1) HRP20221303T1 (da)
HU (1) HUE060369T2 (da)
PL (2) PL2812431T3 (da)
PT (2) PT3591047T (da)
WO (1) WO2013119947A1 (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
EP2791322A1 (en) 2011-12-12 2014-10-22 Cell Medica Limited Process of expanding t cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (da) 2012-02-09 2019-10-14 Baylor College Medicine Peptidblandinger til generering af multivirale ctl'er med bred specificitet
IL288241B2 (en) * 2012-06-11 2023-10-01 Wilson Wolf Mfg Corporation Improved cell culture methods for stress cell therapy
CA2998649A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
JP6697076B2 (ja) * 2015-10-22 2020-05-20 ルーカス・バイオ・カンパニー・リミテッド ウイルス抗原特異的ｔ細胞の濃縮および拡大方法
US20200316119A1 (en) * 2016-05-23 2020-10-08 The Counsil of the Queensland Institute of Medical REsearch Cmv epitopes
US20210252128A1 (en) * 2016-07-18 2021-08-19 The Council Of The Queensland Institute Of Medical Research Multivirus-specific t cell immunotherapy
WO2018052947A1 (en) * 2016-09-16 2018-03-22 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells
US10821134B2 (en) 2017-05-17 2020-11-03 Board Of Regents, The University Of Texas System BK virus specific T cells
AU2020247987A1 (en) * 2019-03-25 2021-11-11 Baylor College Of Medicine Multi-respiratory virus antigen-specific T cells and methods of making and using the same therapeutically
KR20210152515A (ko) 2019-04-12 2021-12-15 씨4 테라퓨틱스, 인코포레이티드 이카로스 및 아이올로스의 트리시클릭 분해제
US10772914B1 (en) * 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
EP3976068A4 (en) * 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
KR20220048021A (ko) * 2019-08-16 2022-04-19 베이롤 칼리지 오브 메드신 제3자 바이러스-특이적 t 세포 조성물, 이의 제조방법 및 이의 항바이러스 예방에서의 사용 방법
EP4061386A4 (en) * 2019-11-19 2024-01-10 Acibadem Labmed Saglik Hizmetleri Anonim Sirketi METHOD FOR PRODUCING MULTIVIRUS-SPECIFIC T CELLS
EP4081226A4 (en) * 2019-12-23 2024-03-27 Baylor College of Medicine T CELL PERFORMANCE ASSAY AS A PROGNOSIS FACTOR FOR CLINICAL OUTCOME
EP4121514A1 (en) 2020-03-20 2023-01-25 Baylor College of Medicine Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections
CN113564116B (zh) * 2021-07-21 2023-08-01 北京赛傲生物技术有限公司 特异性抗病毒过继免疫细胞ce的制备方法
WO2023224599A1 (en) 2022-05-16 2023-11-23 Allovir, Inc. Multivirus-specific t cell compositions and their use in treating or preventing viral infection or disease in solid organ transplant recipients
TW202408549A (zh) 2022-05-16 2024-03-01 美商艾洛維爾公司 多病毒特異性t細胞組合物及其於治療或預防實體器官移植接受者中之病毒感染或疾病的用途
JP2026017056A (ja) * 2024-07-23 2026-02-04 瑞愛生醫股▲ふん▼有限公司 Ｔ細胞増殖のための無血清処方

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641628A (en) 1989-11-13 1997-06-24 Children's Medical Center Corporation Non-invasive method for isolation and detection of fetal DNA
AU4678993A (en) 1992-07-16 1994-02-14 Board Of Trustees Of The Leland Stanford Junior University Methods for using dendritic cells to activate t cells
US6821778B1 (en) 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
WO1995024217A1 (en) 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
AUPM446594A0 (en) 1994-03-16 1994-04-14 Csl Limited Cytotoxic t-cell epitopes identified within epstein-barr virus
ATE196315T1 (de) 1994-04-06 2000-09-15 Immunex Corp Interleukin-15
AU691501B2 (en) 1994-05-16 1998-05-21 Boehringer Mannheim Gmbh Method of immunomodulation by means of adoptive transfer of antigen-specific cytotoxic T-cells
US6300090B1 (en) 1994-07-29 2001-10-09 The Rockefeller University Methods of use of viral vectors to deliver antigen to dendritic cells
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
ATE211172T1 (de) 1995-06-06 2002-01-15 Organon Teknika Bv Epstein-barr viruspeptide, und antikörper gegen diese peptide
FR2745185B1 (fr) 1996-02-28 1998-05-15 Sanofi Sa Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant
US6699477B2 (en) 1996-05-24 2004-03-02 The Council Of The Queensland Institute Of Medical Research EBV CTL epitopes
US5962318A (en) 1996-11-15 1999-10-05 St. Jude Children's Research Hospital Cytotoxic T lymphocyte-mediated immunotherapy
AU6140998A (en) 1997-01-31 1998-08-25 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
AU7256498A (en) 1997-04-25 1998-11-24 Wistar Institute Of Anatomy And Biology, The Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
AUPO784197A0 (en) 1997-07-10 1997-08-07 Csl Limited Treatment of nasopharyngeal carcinoma
DE69840739D1 (de) 1997-10-27 2009-05-28 Merix Bioscience Inc Methode und Zusammensetzung zur Herstellung von reifen dendritischen Zellen
US20020155108A1 (en) 1998-05-04 2002-10-24 Biocrystal, Ltd. Method for ex vivo loading of antigen presenting cells with antigen, and a vaccine comprising the loaded cells
WO2000050569A1 (en) 1999-02-24 2000-08-31 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US6828147B1 (en) 1999-02-24 2004-12-07 The Wistar Institute Of Anatomy And Biology Method of modifying cytotoxic cells and uses thereof
US7005131B1 (en) 1999-08-13 2006-02-28 The Rockefeller University Protective antigen of Epstein Barr Virus
US20150037297A1 (en) 1999-08-30 2015-02-05 David S Terman Sickled Erythrocytes and Progenitors Target Cytotoxics to Tumors
JP2003519473A (ja) 1999-11-24 2003-06-24 アーネスト ジー． ホープ 癌治療のための抗血管形成細胞性物質
CN102766605A (zh) 1999-12-10 2012-11-07 由卫生与公众服务部代表的美利坚合众国政府 重组副流感病毒(piv)作为载体提供保护对抗piv及其他人类病原体引起的感染和疾病的用途
DE10009341A1 (de) 2000-02-22 2001-09-06 Florian Kern Verfahren zur antigen-spezifischen Stimulation von T-Lymphozyten
US20020155127A1 (en) 2000-06-02 2002-10-24 Danher Wang Genetic vaccine against human immunodeficiency virus
DK2336187T3 (da) 2000-06-19 2016-08-22 Beth Israel Deaconess Medical Ct Inc Sammensætninger og fremgangsmåder med monoklonale og polyklonale antistoffer, der er specifikke for T-cellesubpopulationer
CA2422454A1 (en) 2000-09-15 2002-03-21 Ortho-Mcneil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
EP1229043A1 (en) 2001-01-30 2002-08-07 Cyto-Barr B.V. Peptides derived from Epstein Barr virus (EBV) proteins LMP1, LMP2 and BARF1 antibody reagents reactive therewith
GB0107628D0 (en) 2001-03-27 2001-05-16 Avidex Ltd Substances
US20040022761A1 (en) 2001-05-11 2004-02-05 Banchereau Jacques F Compositions and methods for producing antigen-presenting cells
EP2687593A1 (en) 2001-05-15 2014-01-22 Ortho-McNeil Pharmaceutical, Inc. Ex-vivo priming for generating cytotoxic T lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease
UA75429C2 (en) 2001-09-28 2006-04-17 Mowing blade
WO2003042377A1 (en) 2001-11-07 2003-05-22 Kirin Beer Kabushiki Kaisha Expansion of t cells in vitro and expanded t cell populations
US20030148982A1 (en) 2001-11-13 2003-08-07 Brenner Malcolm K. Bi-spcific chimeric T cells
RU2313365C2 (ru) 2001-11-29 2007-12-27 Дандрит Байотек А/С Фармацевтическая композиция для индукции иммунной реакции у человека
US20040096457A1 (en) 2001-12-11 2004-05-20 Huber Brigitte T Treatment and prevention of ebv infection and ebv-associated disorders
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US7638325B2 (en) 2002-01-03 2009-12-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform
WO2004041849A1 (en) 2002-11-07 2004-05-21 The Council Of The Queensland Institute Of Medical Research Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
AU2002953238A0 (en) 2002-12-09 2003-01-02 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland In vitro immunization
IL158140A0 (en) 2003-09-25 2004-03-28 Hadasit Med Res Service Multiepitope polypeptides for cancer immunotherapy
EP2336293B1 (en) 2003-10-08 2016-02-10 Wilson Wolf Manufacturing Corporation Cell culture methods and devices utilizing gas permeable materials
US20050221481A1 (en) 2004-03-30 2005-10-06 Istituto Superiore Di Sanita' Amplification of T cells from human cord blood in serum-deprived culture stimulated with stem cell factor, interleukin-7 and interleukin-2
US7785806B2 (en) 2004-04-28 2010-08-31 Vaxdesign Corporation Method for determining the immunogenicity of an antigen
WO2005118788A2 (en) 2004-05-27 2005-12-15 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
US7785875B2 (en) 2004-07-03 2010-08-31 Mogam Biotechnology Research Institute Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
US20060045883A1 (en) 2004-08-26 2006-03-02 Jeffrey Molldrem Anti-cancer vaccines
JP4731867B2 (ja) 2004-10-01 2011-07-27 国立大学法人三重大学 Ｃｄ８陽性の細胞傷害性ｔリンパ球の誘導方法
US20060204509A1 (en) 2005-03-14 2006-09-14 Harty John T Accelerated CD8+ T-cell memory after dendritic cell vaccination
EP1712615A1 (en) 2005-04-15 2006-10-18 Txcell In vitro production of a cell population using feeder cells
ES2334936T3 (es) 2005-04-20 2010-03-17 F. Hoffmann-La Roche Ag Metodo de identificacion de epitopos relacionados con la inmunogenicidad en biofarmacos.
WO2006124412A2 (en) 2005-05-11 2006-11-23 The Trustees Of The University Of Pennsylvania Methods for the rapid expansion of antigen specific t-cells
US20070003531A1 (en) 2005-06-30 2007-01-04 University Of Connecticut Methods for improving immunotherapy by enhancing survival of antigen-specific cytotoxic T lymphocytes
US20100035282A1 (en) 2005-08-03 2010-02-11 Maria Chiara Bonini Use of common gamma chain cytokines for the visualization, isolation and genetic modification of memory t lymphocytes
JP4824389B2 (ja) * 2005-10-28 2011-11-30 株式会社医学生物学研究所 エプスタイン−バールウイルス感染細胞を特異的に攻撃する細胞傷害性ｔ細胞エピトープペプチド及びその用途
AU2006338570B2 (en) 2005-11-18 2013-07-11 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
GB0604170D0 (en) 2006-03-02 2006-04-12 Antitope Ltd T cell assays
PT1989544E (pt) 2006-03-02 2011-09-26 Antitope Ltd Ensaios com células t
WO2007121276A2 (en) 2006-04-12 2007-10-25 Biocept, Inc. Enrichment of circulating fetal dna
WO2008025992A2 (en) 2006-09-01 2008-03-06 Cambridge Enterprise Limited Methods of expanding non-effector cd8 t-cell populations
EP2476696A3 (en) 2006-11-22 2012-11-07 Board of Trustees of the University of Arkansas Multi-epitope peptide-loaded dendritic cell immunotherapy for cancer
AU2007332869B2 (en) 2006-12-07 2012-10-11 Wilson Wolf Manufacturing, LLC Highly efficient gas permeable devices and methods for culturing cells
DK2117571T3 (da) 2006-12-08 2017-05-08 Monopar Therapeutics Inc Urokinase-type plasminogenaktivatorreceptorepitop
DE102006060824B4 (de) 2006-12-21 2011-06-01 Johannes-Gutenberg-Universität Mainz Nachweis von individuellen T-Zell-Reaktionsmustern gegen Tumor-assoziierte Antigene (TAA) in Tumorpatienten als Basis für die individuelle therapeutische Vakzinierung von Patienten
WO2008148170A1 (en) 2007-06-08 2008-12-11 The University Of Queensland Human metapneumovirus immunogenic peptides, compositions, and methods of use
EP2205252B1 (en) 2007-09-27 2017-04-05 The Board Of Trustees Of The University Of Arkansas Inhibition of dendritic cell-driven regulatory t cell activation and potentiation of tumor antigen-specific t cell responses by interleukin-15 and map kinase inhibitor
EP2060583A1 (en) 2007-10-23 2009-05-20 Ganymed Pharmaceuticals AG Identification of tumor-associated markers for diagnosis and therapy
EP2207875A1 (en) 2007-10-24 2010-07-21 Anne Letsch Antigen-specific t-cell preparations from bone marrow
WO2009059011A2 (en) 2007-11-01 2009-05-07 Mayo Foundation For Medical Education And Research Hla-dr binding peptides and their uses
EP2065462A1 (en) 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
WO2010030947A1 (en) 2008-09-11 2010-03-18 University Of Florida Research Foundation, Inc. System and method for producing t cells
CN101824400B (zh) 2009-03-05 2012-08-08 中国科学院微生物研究所 一种放大增殖抗原特异性t细胞的方法
CN102625832A (zh) 2009-08-24 2012-08-01 贝勒医学院 产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
JP5833443B2 (ja) 2009-08-29 2015-12-16 株式会社バイオメッドコア 抗原特異的ｔ細胞誘導能測定法
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
US20130115617A1 (en) 2009-12-08 2013-05-09 John R. Wilson Methods of cell culture for adoptive cell therapy
US8956860B2 (en) 2009-12-08 2015-02-17 Juan F. Vera Methods of cell culture for adoptive cell therapy
US8809050B2 (en) 2009-12-08 2014-08-19 Wilson Wolf Manufacturing Methods of cell culture for adoptive cell therapy
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
US9114100B2 (en) 2010-05-17 2015-08-25 Duke University Methods of treatment using ex vivo expansion of cord blood T cells
EP2600890A1 (en) 2010-08-04 2013-06-12 Instituto Europeo di Oncologia S.r.l. Method of antigen loading for immunotherapy
WO2012054792A2 (en) 2010-10-22 2012-04-26 Virginia Commonwealth University Composition and method for immunological treatment of cancer, prevention of cancer recurrence and metastasis, and overcoming immune suppressor cells
EP2453243A1 (en) 2010-11-11 2012-05-16 Cosmo S.p.A. Method for the diagnosis and/or follow up of the evolution of a tumor
US20130045491A1 (en) 2011-07-19 2013-02-21 Derya Unutmaz Methods for activating t cells
AU2012305931B2 (en) 2011-09-08 2017-09-07 Yeda Research And Development Co. Ltd Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatment
EP2791322A1 (en) 2011-12-12 2014-10-22 Cell Medica Limited Process of expanding t cells
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
DK2812431T3 (da) 2012-02-09 2019-10-14 Baylor College Medicine Peptidblandinger til generering af multivirale ctl'er med bred specificitet
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
JP6445427B2 (ja) 2012-05-08 2018-12-26 ウエスタン ユニバーシティ オブ ヘルス サイエンシズ ＣＤ４＋Ｔ細胞集団の抗原特異的な拡大のために標準化されたｅｘｖｉｖｏプラットフォーム
US10357515B2 (en) 2013-11-22 2019-07-23 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
WO2015110397A2 (en) 2014-01-21 2015-07-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for testing t cell priming efficacy in a subject
WO2016073595A1 (en) 2014-11-05 2016-05-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services T cells and dendritic cells for polyomavirus therapy
CN119345231A (zh) 2014-11-05 2025-01-24 纪念斯隆-凯特林癌症中心 选择用于过继细胞疗法的t细胞系及其供体的方法
WO2016154112A1 (en) 2015-03-20 2016-09-29 Children's National Medical Center Generating virus or other antigen-specific t cells from a naive t cell population
EP3756676B1 (en) 2015-06-26 2023-01-11 Memorial Sloan Kettering Cancer Center Methods of treating cmv retinitis by t cell therapy
CA2998649A1 (en) 2015-09-18 2017-03-23 Baylor College Of Medicine Immunogenic antigen identification from a pathogen and correlation to clinical efficacy
IL262989B2 (en) 2016-05-25 2025-08-01 Council Queensland Inst Medical Res Methods for treating autoimmune disease using allogeneic T cells
EP3487990A4 (en) 2016-06-28 2020-07-29 Geneius Biotechnology, Inc. T-LYMPHOCYTE COMPOSITIONS FOR IMMUNOTHERAPY
WO2018052947A1 (en) 2016-09-16 2018-03-22 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells
WO2018055191A1 (en) 2016-09-26 2018-03-29 Tessa Therapeutics Pte. Ltd. T cell expansion method
EP3641807A4 (en) 2017-06-22 2021-04-21 The Westmead Institute For Medical Research Adoptive t cell therapy 2
US11646103B2 (en) 2017-09-06 2023-05-09 Nant Holdings Ip, Llc HLA tissue matching and methods therefor
GB201808651D0 (en) 2018-05-25 2018-07-11 Rolls Royce Plc Rotor blade arrangement
AU2020247987A1 (en) 2019-03-25 2021-11-11 Baylor College Of Medicine Multi-respiratory virus antigen-specific T cells and methods of making and using the same therapeutically
TWI777160B (zh) 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
US20220305118A1 (en) 2019-06-20 2022-09-29 Janssen Sciences Ireland Unlimited Company Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines
US20220257654A1 (en) 2019-07-23 2022-08-18 Baylor College Of Medicine Antigen-specific t cell banks and methods of making and using the same therapeutically
CN114502180A (zh) 2019-07-29 2022-05-13 贝勒医学院 抗原特异性t细胞库及其制备和治疗使用方法
KR20220048021A (ko) 2019-08-16 2022-04-19 베이롤 칼리지 오브 메드신 제3자 바이러스-특이적 t 세포 조성물, 이의 제조방법 및 이의 항바이러스 예방에서의 사용 방법
EP4081226A4 (en) 2019-12-23 2024-03-27 Baylor College of Medicine T CELL PERFORMANCE ASSAY AS A PROGNOSIS FACTOR FOR CLINICAL OUTCOME
EP4121514A1 (en) 2020-03-20 2023-01-25 Baylor College of Medicine Sars-cov2-specific t cell compositions and their use in treating and preventing coronavirus and other respiratory virus infections
EP3974029A1 (en) 2020-09-25 2022-03-30 Universidad Autónoma de Madrid Memory t cells as adoptive cell therapy for viral infections
CA3251962A1 (en) 2022-02-15 2023-08-24 Marker Therapeutics, Inc. COMPOSITIONS AND METHODS FOR THE MULTIPLICATION OF ANTIGEN-SPECIFIC T LYMPHOCYTES

Also Published As

Publication number Publication date
PT3591047T (pt) 2022-10-20
EP3591047A1 (en) 2020-01-08
US20150010519A1 (en) 2015-01-08
PL3591047T3 (pl) 2022-12-05
EP3591047B1 (en) 2022-08-03
EP2812431A1 (en) 2014-12-17
US12227764B2 (en) 2025-02-18
ES2748652T3 (es) 2020-03-17
HRP20221303T1 (hr) 2022-12-23
HUE060369T2 (hu) 2023-02-28
EP4089167A1 (en) 2022-11-16
DK3591047T3 (da) 2022-10-24
PL2812431T3 (pl) 2020-02-28
US11981923B2 (en) 2024-05-14
US20220251508A1 (en) 2022-08-11
US20210348127A1 (en) 2021-11-11
PT2812431T (pt) 2019-10-18
US20180187152A1 (en) 2018-07-05
EP2812431A4 (en) 2015-08-19
EP2812431B1 (en) 2019-07-17
WO2013119947A1 (en) 2013-08-15
ES2928851T3 (es) 2022-11-23
US11118164B2 (en) 2021-09-14

Similar Documents

Publication Publication Date Title
DK2812431T3 (da) Peptidblandinger til generering af multivirale ctl'er med bred specificitet
HUS2000032I1 (hu) Helyettesített 4-fenil-piridinek NK-1 receptorral kapcsolatos betegségek kezelésére
DK3725778T4 (da) Formuleringer af enzalutamid
FI20116181L (fi) Uusia terapeuttisia vektoreita
DK2714004T3 (da) Peptidformuleringer med kontrolleret frigivelse
DK3238709T3 (da) Forbedrede parenterale formuleringer af lipofile farmaceutiske midler og fremgangsmåder til fremstilling og anvendelse af samme
DK2895466T3 (da) Fremgangsmåde til syntese af thyreoideahormonanaloger og polymorfer deraf
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK3235812T3 (da) Deutererede derivater af ivacaftor
HUE043088T2 (hu) Halikondrin B analógok szintézisében alkalmazható eljárások
DK2872491T3 (da) Inhibitorer af fibroblastvækstfaktorreceptoren
HUE037048T2 (hu) Eljárások 4-cikloalkiloxibenzolszulfonamidok elõállítására
DK2787975T3 (da) Robuste formuleringer med kontrolleret frigivelse
DK3656758T3 (da) Mellemprodukter til fremstilling af c-terminale hsp90-inhibitorer
SI3513806T1 (sl) Sestava imunogena
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
DK3494993T3 (da) Ny anvendelse af maltotriosyl-transferase
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
LT3246325T (lt) 2-acilaminotiazolo junginio kristalai
EP2844171A4 (en) OUTPUT OF FASTENERS
HUE036319T2 (hu) 2-karboxamid-cikloamino-karbamidszármazékok szintézise
DK2526080T3 (da) Nye fremgangsmåder til fremstilling af benzophenonderivater
DK2571843T3 (da) Forbedret fremstilling af chalcon-derivater
HRP20182057T1 (hr) Temperaturno stabilni vodeni pripravci klokintocet-meksila
DK2736487T4 (da) Nye (trimethoxyphenylamino)pyrimidinyl-formuleringer